COSTA MESA, Calif.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) today announced that Dr. Robert F. Diegelmann, PhD will become the head of the new wound care division being established by the company. The new division’s first priority will be to develop over-the-counter wound treatment applications for Oxycyte®. Oxycyte is the company’s perfluorocarbon (PFC) therapeutic oxygen carrier.
